HKEX:6855 - Ascentage Pharma Group International Ascentage Pharma Grp Internati
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance
Quarterly TTM
Cash Flow Income Statement Key Ratios Personalized

Graphs are exclusive for members only

Sign up for free to access most features of StocksCafe

Show %
2016 2017 2018 2019 2020 2021 2022 2023 Graph
Total Assets [friend] [friend] [friend] [friend] [friend] 2.94B
69.8%
2.83B
-3.7%
2.5B
-11.7%
Current Assets [friend] [friend] [friend] [friend] [friend] 1.89B
74.7%
1.64B
-13.2%
1.34B
-17.9%
Cash+Equi+Others [friend] [friend] [friend] [friend] [friend] 1.71B
67.3%
1.48B
-13.5%
1.07B
-27.5%
NonCurrent Assets [friend] [friend] [friend] [friend] [friend] 1.05B
61.8%
1.19B
13.2%
1.16B
-3.1%
Total Liabilities [friend] [friend] [friend] [friend] [friend] 1.71B
92.8%
2.42B
42.0%
2.43B
0.3%
Current Liabilities [friend] [friend] [friend] [friend] [friend] 361.11M
30.8%
881.15M
144.0%
934.17M
6.0%
NonCurrent Liabilities [friend] [friend] [friend] [friend] [friend] 1.34B
121.0%
1.54B
14.6%
1.5B
-2.9%
Total Equity [friend] [friend] [friend] [friend] [friend] 1.23B
45.8%
408.66M
-66.9%
70.63M
-82.7%
Stockholders Equity [friend] [friend] [friend] [friend] [friend] 1.23B
45.8%
408.66M
-66.9%
60.42M
-85.2%
Minority Interest [friend] [friend] [friend] [friend] [friend] - 0
-
10.22M
-
Values are in CNY whenever applicable | Fiscal year ends on December 31
Powered by Morningstar

Your Holdings
Dashboard
Portfolio
Options

Tools
Screener
Watchlist
Alerts
Notes
Community
Forum
Blog
YouTube
Shared Portfolios
Shared Screeners

Collab with Brokerages
Moomoo x StocksCafe
Tiger x StocksCafe

Help
Quickstart Guides
StocksCafe Academy
StocksCafe Youtube Channel

About StocksCafe
Our Story
Send Feedback
Pricing
Market
Singapore
Hong Kong
Tokyo
Kuala Lumpur
United States
London
Shenzhen
Shanghai
Indexes
Singapore Savings Bonds
Singapore T-Bills
CoinGecko
Your Account
Settings
Subscriptions
Referrals
Messages
Profile
YouTube
Server T1

About · FAQs · StocksCafe © 2024 · Privacy · Terms